The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industries Direct’s proprietary databases, ProStrakan Group plc’s corporate website, SEC filings, investor presentations and featured press releases, both from ProStrakan Group plc and market -specific third party sources, put together by Global Industries Direct’s team.

Scope of the Research

- ProStrakan Group plc - Brief ProStrakan Group plc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ProStrakan Group plc human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ProStrakan Group plc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ProStrakan Group plc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate ProStrakan Group plc’s strategic position with total access to detailed data on its product pipeline.
- Assess the growth opportunities of ProStrakan Group plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ProStrakan Group plc’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ProStrakan Group plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ProStrakan Group plc and identify potential opportunities in those areas.

Table Of Contents

Table of Contents
Data table of Contents 2
List of Tables 4
List of Figures 6
ProStrakan Group plc Snapshot 7
ProStrakan Group plc Overview 7
Key Information 7
Key Facts 7
ProStrakan Group plc - Research and Development Overview 8
Key Therapeutic Areas 8
ProStrakan Group plc - Pipeline Review 10
Pipeline Products by Stage of Development 10
ProStrakan Group plc - Pipeline Products Glance 11
ProStrakan Group plc - Late Stage Pipeline 11
Registration Filed Products/Combination Treatment Modalities 11
Phase III Products/Combination Treatment Modalities 12
ProStrakan Group plc Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
ProStrakan Group plc - Drug Profiles 14
Sancuso 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Testosterone-Glucoside 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
ProStrakan Group plc - Pipeline Analysis 16
ProStrakan Group plc - Pipeline Products by Therapeutic Class 16
ProStrakan Group plc - Pipeline Products By Target 17
ProStrakan Group plc - Pipeline Products by Route of Administration 18
ProStrakan Group plc - Pipeline Products by Molecule Type 19
ProStrakan Group plc - Recent Pipeline Updates 20
ProStrakan Group plc - Dormant Projects 21
ProStrakan Group plc - Firms Statement 22
ProStrakan Group plc - Operations and Subsidiaries 27
Head Office 27
Other Locations and Subsidiaries 27
Recent Developments 29
April 27, 2004: Strakan Initiates Phase I Trial Of Testosterone-Glucoside 29
December 26, 2004: FDA Issues Not Approvable Letter For Cellegesic - Cellegy Pharmaceuticals 29
June 25, 2009: ProStrakan Announces Publication of Notice of Allowance for Sancuso US Patent 29
May 23, 2008: ProStrakan and JapanBridge Partner to Develop Sancuso in Japan, China and Parts of South East Asia 30
April 23, 2008: FDA Moves Sancuso PDUFA Date to mid-June e 30
December 22, 2008: ProStrakan Announces Outlicensing of Abstral and Sancuso in Canada 30
June 22, 2011: ProStrakan Receives FDA Approval For Rectiv For Treatment Of Moderate To Severe Pain Associated With Chronic Anal Fissures 31
October 21, 2009: ProStrakan Announces FDA Acceptance of US Submission of Cellegesic (Nitroglycerin) 0.4% Ointment 31
August 20, 2007: ProStrakan Announces Commencement Of Recruitment In Pivotal US Trials For Cellegesic (Rectogesic) 32
July 18, 2008: Sancuso - PDUFA Action Date March ket Update 32
September 15, 2008: ProStrakan Receives US FDA Approval for Sancuso 32
August 13, 2007: ProStrakan Announces LG Life Sciences as South Korean Partner for Sancuso 33
January 12, 2006: Adcal D3 takes industry lead 33
July 11, 2008: New PDUFA Action Date for Sancuso 33
July 11, 2006: FDA Issusses Approvable Letter To Cellegy Pharmaceuticals For Cellegesic 34
February 09, 2009: ProStrakan Announces Further Outlicensing Deals in Globalisation of Sancuso 34
May 05, 2009: ProStrakan Announces US Submission Of Fortigel (Testosterone) 2% Gel 34
December 03, 2007: ProStrakan Receives Approval for Adcal-D3 Dissolve 35
November 03, 2008: ProStrakan Launches Sancuso in US 35
June 02, 2008: Update on Sancuso US Regulatory Review Status 36
April 01, 2010: ProStrakan Receives Complete Response Letter For Rectogesic From FDA 36
Financial Deals Landscape 38
ProStrakan Group plc, Merger and Acquisition Deal Summary 38
ProStrakan Group plc, Pharmaceuticals and Healthcare, Merger and Acquisition Deal Details 41
Asset Transactions 41
ProStrakan Takes Over Expanded Rights To Rectogesic and Tostran From Cellegy Pharmaceuticals 41
Private Equity 43
ProStrakan Raise US$ 39.76 Mln 43
Partnerships 45
Endo Pharmaceuticals Signs Licensing Agreement With ProStrakan Group 45
ProStrakan Enters Into Co-March keting Agreement With EKR Therapeutics 46
ProStrakan Forms Partnership With November aQuest 47
ProStrakan Concludes a new deal With LG Life Sciences 48
ProStrakan Forms Joint Venture With Orexo 49
ProStrakan Enters Into Distribution Agreement With Gedeon Richter 50
TiGenix Enters Into Co-Development Agreement With ProStrakan 51
Merger 52
Strakan Merges With Proskelia 52
Licensing Agreements 53
Abeille Pharmaceuticals Enters Into Licensing Agreement With Prostrakan 53
ProStrakan Enters Into Licensing Agreement with Genus Pharmaceuticals 54
ProStrakan Enters Into Sub-Licensing Agreement With Cantabria Farmaceutica 55
Paladin Labs Enters Into Licensing Agreement With ProStrakan Group 56
Paladin Labs Enters Into Licensing Agreement With ProStrakan 58
Bayer Schering Signs License Agreement With ProStrakan Group 60
ProStrakan Enters Into License Agreement With NewBridge 61
Orexo Extends Its Licensing Agreement With ProStrakan 62
ProStrakan Enters Into Licensing Agreement With JapanBridge 63
ProStrakan Enters Into Licensing Agreement With Torrex Chiesi Pharma 64
ProStrakan Enters Into Licensing And Distribution Agreement With Ferring 65
ProStrakan Enters Into Licensing Agreement With November artis 66
ProStrakan Enters Into Licensing Agreement With Amgen 67
ProStrakan Amends Licensing Agreement With Cellegy Pharmaceuticals 68
Cellegy Pharmaceuticals Amends License Agreement With ProStrakan For Tostrex 69
ProStrakan Enters Into Licensing Agreement With Orexo 70
ProStrakan Amends Licensing Agreement With Cellegy Pharmaceuticals For Rectogesic 71
ProStrakan Enters Into Licensing Agreement With Cellegy Pharmaceuticals For Rectogesic 72
Clinuvel Pharmaceuticals Enters Into Licensing Agreement With Strakan Pharmaceuticals 73
Cellegy Pharmaceuticals Enters Into Licensing Agreement With Strakan Pharmaceuticals For Tostrex 74
Equity Offering 75
ProStrakan Completes Private Placement Of US$ 20.8 Mln 75
Asset Transactions 76
Crawford Healthcare Takes Over Zindaclin From ULURU And Strakan 76
ProStrakan Sells Its Product Zindaclin To Crawford Healthcare 78
Acquisition 79
Kyowa Hakko Kirin Completes Acquisition Of ProStrakan 79
Norgine Takes Over 12.61% Stake In ProStrakan 83
MDY Healthcare Takes Over Minority Stake In ProStrakan Group 85
ProStrakan Group Sells ProSkelia To Galapagos 87
ProStrakan Takes Over APS Pharma 89
ProStrakan Takes Over Elfar 90
Prostrakan Takes Over OTL Pharma 91
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 93
Contact Us 93
Disclaimer 93

List of Tables

ProStrakan Group plc - Pipeline by Therapy Area and Indication, H2 2011 9
ProStrakan Group plc - Pipeline by Stage of Development, H2 2011 10
ProStrakan Group plc - Filed, H2 2011 11
ProStrakan Group plc - Phase III, H2 2011 12
ProStrakan Group plc - Phase II, H2 2011 13
ProStrakan Group plc - Pipeline By Therapeutic Class, H2 2011 16
ProStrakan Group plc - Pipeline By Target, H2 2011 17
ProStrakan Group plc - Pipeline By Route of Administration, H2 2011 18
ProStrakan Group plc - Pipeline By Molecule Type, H2 2011 19
ProStrakan Group plc - Recent Pipeline Updates, H2 2011 20
ProStrakan Group plc - Dormant Developmental Projects, 2010 21
ProStrakan Group plc, Other Locations 27
ProStrakan Group plc, Subsidiaries 28
ProStrakan Group plc, Merger and Acquisition Deal Summary 38
ProStrakan Takes Over Expanded Rights To Rectogesic and Tostran From Cellegy Pharmaceuticals 41
ProStrakan Raise US$ 39.76 Mln 43
Endo Pharmaceuticals Signs Licensing Agreement With ProStrakan Group 45
ProStrakan Enters Into Co-March keting Agreement With EKR Therapeutics 46
ProStrakan Forms Partnership With November aQuest 47
ProStrakan Concludes a new deal With LG Life Sciences 48
ProStrakan Forms Joint Venture With Orexo 49
ProStrakan Enters Into Distribution Agreement With Gedeon Richter 50
TiGenix Enters Into Co-Development Agreement With ProStrakan 51
Strakan Merges With Proskelia 52
Abeille Pharmaceuticals Enters Into Licensing Agreement With Prostrakan 53
ProStrakan Enters Into Licensing Agreement with Genus Pharmaceuticals 54
ProStrakan Enters Into Sub-Licensing Agreement With Cantabria Farmaceutica 55
Paladin Labs Enters Into Licensing Agreement With ProStrakan Group 56
Paladin Labs Enters Into Licensing Agreement With ProStrakan 58
Bayer Schering Signs License Agreement With ProStrakan Group 60
ProStrakan Enters Into License Agreement With NewBridge 61
Orexo Extends Its Licensing Agreement With ProStrakan 62
ProStrakan Enters Into Licensing Agreement With JapanBridge 63
ProStrakan Enters Into Licensing Agreement With Torrex Chiesi Pharma 64
ProStrakan Enters Into Licensing And Distribution Agreement With Ferring 65
ProStrakan Enters Into Licensing Agreement With November artis 66
ProStrakan Enters Into Licensing Agreement With Amgen 67
ProStrakan Amends Licensing Agreement With Cellegy Pharmaceuticals 68
Cellegy Pharmaceuticals Amends License Agreement With ProStrakan For Tostrex 69
ProStrakan Enters Into Licensing Agreement With Orexo 70
ProStrakan Amends Licensing Agreement With Cellegy Pharmaceuticals For Rectogesic 71
ProStrakan Enters Into Licensing Agreement With Cellegy Pharmaceuticals For Rectogesic 72
Clinuvel Pharmaceuticals Enters Into Licensing Agreement With Strakan Pharmaceuticals 73
Cellegy Pharmaceuticals Enters Into Licensing Agreement With Strakan Pharmaceuticals For Tostrex 74
ProStrakan Completes Private Placement Of US$ 20.8 Mln 75
Crawford Healthcare Takes Over Zindaclin From ULURU And Strakan 76
ProStrakan Sells Its Product Zindaclin To Crawford Healthcare 78
Kyowa Hakko Kirin Completes Acquisition Of ProStrakan 79
Norgine Takes Over 12.61% Stake In ProStrakan 83
MDY Healthcare Takes Over Minority Stake In ProStrakan Group 85
ProStrakan Group Sells ProSkelia To Galapagos 87
ProStrakan Takes Over APS Pharma 89
ProStrakan Takes Over Elfar 90
Prostrakan Takes Over OTL Pharma 91

List of Figures

ProStrakan Group plc - Pipeline by Therapy Area and Indication, H2 2011 9
ProStrakan Group plc - Pipeline by Stage of Development, H2 2011 10
ProStrakan Group plc - Pipeline By Therapeutic Class, H2 2011 16
ProStrakan Group plc - Pipeline By Target, H2 2011 17
ProStrakan Group plc - Pipeline By Route of Administration, H2 2011 18
ProStrakan Group plc - Pipeline By Molecule Type, H2 2011 19

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Jazz Pharmaceuticals plc - Product Pipeline Review - 2014

Jazz Pharmaceuticals plc - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • May 2014
  • by Global Markets Direct

Jazz Pharmaceuticals plc - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘Jazz Pharmaceuticals plc - Product Pipeline Review - 2014', provides an overview of the Jazz Pharmaceuticals ...

Vernalis plc - Product Pipeline Review - 2014

Vernalis plc - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • May 2014
  • by Global Markets Direct

Vernalis plc - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘Vernalis plc - Product Pipeline Review - 2014', provides an overview of the Vernalis plc's pharmaceutical research and ...

Oxford BioMedica plc - Product Pipeline Review - 2014

Oxford BioMedica plc - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • May 2014
  • by Global Markets Direct

Oxford BioMedica plc - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘Oxford BioMedica plc - Product Pipeline Review - 2014', provides an overview of the Oxford BioMedica plc's pharmaceutical ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.